Group 1: Clinical Trials and Research Progress - The company is actively promoting the CKBA clinical trial for vitiligo, aiming to start by the end of 2025 [2] - The IIT study for vitiligo in children aged 2-12 is progressing, with data expected in Q4 of this year [2] - The company plans to initiate clinical trials for CKBA in treating rosacea once the II/III phase trial approval is obtained [3] Group 2: Financial Performance and Dividends - The company has maintained a stable cash dividend ratio, proposing a dividend of 2 CNY per 10 shares for the 2024 fiscal year [4] - Recent increases in R&D investment and declining sales in men's health products have led to short-term performance pressure [5] - The company is focusing on launching high-potential generic drugs to create new profit growth points [5] Group 3: Employee Stock Plan and Disclosure - The employee stock plan will disclose purchase details monthly for six months after approval at the shareholders' meeting [5] - The company is committed to adhering to disclosure regulations regarding the employee stock plan [5] - No undisclosed significant information was revealed during the earnings presentation [6]

Core Viewpoint - The performance of the Zhongzheng 2000 ETF managed by Jiashi Fund has shown a decline in its share price and mixed results among its major holdings since its inception on September 14, 2023 [1] Group 1: ETF Performance - As of the midday close on September 19, the Zhongzheng 2000 ETF Jiashi (159535) decreased by 0.92%, trading at 1.395 yuan with a transaction volume of 453,100 yuan [1] - Since its establishment, the fund has achieved a return of 40.87%, with a monthly return of 1.85% [1] Group 2: Major Holdings Performance - Major stocks within the ETF include: - Meiri Hudong down 0.31% - Hanwei Technology down 7.97% - Hongchuang Holdings up 5.27% - Dongtu Technology down 1.34% - Hengbao Shares down 5.53% - Taiji Shares down 0.72% - Rejing Biology down 4.53% - Shijia Photon up 0.67% - Huasheng Tiancai down 4.24% - Tainkang up 1.49% [1]

Group 1 - Shudao Equipment's subsidiary signed a construction contract worth 24.68 million yuan for a hydrogen fuel cell manufacturing base project [1] - Zhongliang Technology received a land acquisition compensation of 30 million yuan from the government [2] - Palm Holdings won a bid for a high-standard farmland construction project in Lankao County, with a contract value of 433 million yuan, accounting for 14.12% of the company's audited revenue for 2024 [3] Group 2 - Changchun Yidong's subsidiary received a government subsidy of 2.85 million yuan, which is 122.78% of the company's audited net profit for the last fiscal year [4] - Wuzhou Transportation successfully issued 200 million yuan in medium-term notes with an interest rate of 2.10% [5][6] - Tiandi Source's subsidiary plans to apply for a trust loan of up to 500 million yuan from related parties [8] Group 3 - Tiandi Source's subsidiary acquired a residential land use right in Xi'an for 2.015 billion yuan [9] - Opcon Vision received a medical device registration certificate for its ultrasonic nebulizer [11] - Jingjiawei announced the resignation of its vice president due to personal reasons [13] Group 4 - Fulinh Precision's subsidiary received a prepayment of 1.5 billion yuan from CATL for securing lithium iron phosphate material supply [15] - Yunzhu Technology's subsidiary received a government subsidy of 20.12 million yuan [16] - Kehua Bio's ferritin test kit received a medical device registration certificate [17] Group 5 - Jinghua Pharmaceutical's medical sodium alginate wound dressing received a medical device registration certificate [18] - Lingwei Technology established a wholly-owned subsidiary with a registered capital of 1 million yuan [19] - Sanwei Co. won a bid for concrete sleeper procurement projects worth 158 million yuan [20] Group 6 - Shanghai Pharmaceuticals' Nicardipine tablets passed the consistency evaluation for generic drugs [21] - Lushan New Materials increased its idle fund management limit to 750 million yuan [24] - Huayi Technology announced the retirement of a core technical staff member [25] Group 7 - Yingli Environment plans to use up to 300 million yuan of idle raised funds for cash management [30] - Yong'an Forestry plans to develop a national reserve forest project in Putian, Fujian, with an estimated investment of 154 million yuan [32] - Xinyuan Technology's shareholders plan to reduce their holdings by up to 3.18% of the company's shares [60]

Core Viewpoint - The company TianKang (301263.SZ) has received a notice of acceptance for the drug registration application of Safinamide Mesylate Tablets from the National Medical Products Administration (NMPA) in China, indicating progress in its drug approval process [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application [1] - The acceptance of the application is based on the review conducted by the NMPA according to Article 32 of the Administrative Licensing Law of the People's Republic of China [1] Group 2: Product Information - Safinamide Mesylate Tablets are a selective inhibitor of monoamine oxidase B (MAO-B) and are primarily used for treating adult patients with idiopathic Parkinson's disease (PD) [1] - The drug serves as an adjunct therapy to stable doses of Levodopa (L-dopa) alone or in combination with other PD treatments for patients experiencing mid to late-stage fluctuations [1]

Core Viewpoint - The announcement indicates that Tianen Pharmaceutical has received a production registration approval for Safinamide Mesylate Tablets from the National Medical Products Administration, which is a significant step for the company in expanding its product offerings in the Parkinson's disease treatment market [1]. Company Summary - Tianen Pharmaceutical's wholly-owned subsidiary, Anhui Tianen Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application for Safinamide Mesylate Tablets [1]. - Safinamide Mesylate is a selective MAO-B inhibitor primarily used for treating adult patients with idiopathic Parkinson's disease, serving as an adjunct therapy to stable doses of L-dopa alone or in combination with other PD treatments for patients experiencing mid to late-stage fluctuations [1].

Core Viewpoint - TianKang (301263.SZ) has received the acceptance notice for the drug registration application of Safinamide Mesylate Tablets from the National Medical Products Administration (NMPA) in China, indicating progress in its product pipeline for treating Parkinson's disease [1] Company Summary - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application for Safinamide Mesylate Tablets [1] - The drug is a selective inhibitor of monoamine oxidase B (MAO-B) and is primarily used as an adjunct therapy for adult patients with idiopathic Parkinson's disease (PD) [1] - Safinamide Mesylate Tablets are intended for use in patients experiencing fluctuations in their condition, either alone or in combination with other PD treatments, particularly in the mid to late stages of the disease [1]

Core Viewpoint - The company TianKang (301263.SZ) has received a notice of acceptance for the drug registration application of Safinamide Mesylate Tablets from the National Medical Products Administration (NMPA) in China, indicating progress in its product development for treating Parkinson's disease [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application [1] - The drug, Safinamide Mesylate Tablets, is a selective MAO-B inhibitor intended for the treatment of adult patients with idiopathic Parkinson's disease [1] - The drug is designed to be used as an adjunct therapy with stable doses of Levodopa, either alone or in combination with other Parkinson's disease treatments, particularly for patients experiencing mid to late-stage fluctuations [1]

证券代码：301263 证券简称：泰恩康 公告编号：2025-066 广东泰恩康医药股份有限公司 审核结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审 查，决定予以受理。 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）全资子公司安徽泰恩 康制药有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 签发的甲磺酸沙非胺片境内生产药品注册上市许可申请《受理通知书》，国家 药监局根据《中华人民共和国行政许可法》第三十二条的规定，对上述药品的 药品注册上市许可申请进行了审查，决定予以受理。现将相关情况公告如下： 一、申请注册药品的基本情况 受理号：CYHS2503455、CYHS2503456 药品名称：甲磺酸沙非胺片 申请事项：境内生产药品注册上市许可 许可药品注册分类：化学药品 4 类 规格：50mg、100mg 申请人：安徽泰恩康制药有限公司 二、药品相关情况简介 甲磺酸沙非胺片是一种选择性抑制 B 型单胺氧化酶（MAO-B）抑制剂，主 要用于治疗成年特 ...

Group 1 - The core viewpoint of the news is that 泰恩康's stock has experienced fluctuations, with a notable decline of 2.13% on September 18, 2023, and a significant increase of 145.49% year-to-date [1] - As of September 18, 2023, 泰恩康's stock price is 36.31 CNY per share, with a total market capitalization of 15.45 billion CNY [1] - The company has seen a net outflow of main funds amounting to 20.34 million CNY, with large orders showing a buy of 41.42 million CNY and a sell of 44.88 million CNY [1] Group 2 - For the first half of 2023, 泰恩康 reported a revenue of 34.7 million CNY, a year-on-year decrease of 12.23%, and a net profit attributable to shareholders of 37.08 million CNY, down 56.75% year-on-year [2] - The company has distributed a total of 460 million CNY in dividends since its A-share listing, with 377 million CNY distributed over the past three years [3] Group 3 - 泰恩康's main business segments include pharmaceutical agency (65.16%), pharmaceutical manufacturing (31.70%), and pharmaceutical technology services and technology transfer (2.97%) [1] - The company is categorized under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and chemical preparations [1]

Group 1 - The core viewpoint of the news is that 泰恩康's stock has experienced fluctuations, with a current price of 37.85 yuan per share and a market capitalization of 16.105 billion yuan, despite a significant year-to-date increase of 155.90% [1] - The company has seen a net outflow of main funds amounting to 30.06 thousand yuan, with large orders showing a buy of 829.73 thousand yuan and a sell of 737.58 thousand yuan [1] - 泰恩康's main business revenue composition includes 65.16% from pharmaceutical agency, 31.70% from pharmaceutical manufacturing, and 2.97% from pharmaceutical technology services and technology transfer [1] Group 2 - As of June 30, 泰恩康 had 10,900 shareholders, a decrease of 33.05% from the previous period, with an average of 27,747 circulating shares per person, an increase of 49.36% [2] - For the first half of 2025, 泰恩康 reported operating revenue of 34.7 million yuan, a year-on-year decrease of 12.23%, and a net profit attributable to shareholders of 37.08 million yuan, down 56.75% year-on-year [2] - Since its A-share listing, 泰恩康 has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [3]